https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2023-01-05 08:08:362023-01-05 08:08:36Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2023-01-04 14:38:302023-01-04 14:38:30Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2023-01-04 12:07:452023-01-04 12:07:45ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-21 11:08:372022-12-21 11:08:37Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-20 12:04:442022-12-20 12:04:44IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-20 07:57:072022-12-20 07:57:07Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-15 15:06:052023-06-14 15:49:592022 | Optimum’s Year in Review
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-15 10:17:112022-12-15 10:17:11Cutting-edge protein design project to join BioInnovation Institute’s Bio Studio program
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-15 08:03:002022-12-15 08:03:00MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 11:14:072022-12-14 11:14:07Alchemab Therapeutics | The Chain Podcast
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 09:27:102022-12-15 08:05:24Biocomposites announce a year of record sales and company growth
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-14 08:38:182022-12-14 08:38:18ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 08:18:272022-12-14 08:18:27Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 08:09:412022-12-14 08:09:41STORM Therapeutics announces closing of USD $30M Series B financing
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-13 08:10:522022-12-13 08:10:52Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-13 07:03:092022-12-13 07:03:09Futura Medical provide update on a milestone year of regulatory and commercial progress for MED3000
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-12 10:33:382022-12-12 10:33:38CellCentric presents early clinical data at ASH
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-12 08:02:192022-12-12 10:25:09Poolbeg Pharma plc. POLB 001 LPS human challenge clinical trial successfully completed. No serious adverse events reported. Results of full data analysis expected in Q2 2023
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-07 09:03:062022-12-07 09:03:06Neuraxpharm expands into the Netherlands
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-06 08:35:532022-12-06 08:35:53ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant MelanomaFor more information about Optimum Strategic Communications, please get in touch.
